The National Mesothelioma Law Firm of Baron and Budd Reports on a New Drug that Could Improve the Health of …

Recommended by Dr. Michael White, Updated on May 4th, 2015
Reading Time: 2 minutes

Mesothelioma Lawyers raising awareness of new drug that could help improve the health of mesothelioma patients.

Dallas, TX (PRWEB) December 17, 2012

"This is another step forward in the medical battle against mesothelioma," said John Langdoc, mesothelioma lawyer at Baron and Budd. "Patients and caregivers need to be aware of these newer developments and we are proud to assist in the awareness process."

Currently, mesothelioma doctors typically use a multi-modal approach of surgery, radiation and chemotherapy treatment. The combination of treatments is quite aggressive, and can lead to adverse side affects such as nausea, vomiting, and weight loss. Researchers recently gave the experimental drug Enobosarm, to patients receiving these cancer treatments and reported a significant decrease in muscle loss.

In the Phase IIb clinical trial, Dr. Dobs led a randomized test with 159 subjects given either Enobosarm or a placebo for a total of 16 weeks. Enobosarm is a selective androgen receptor modulator (SARM), a non-steroidal drug that produces the anabolic effect in bone and muscle without causing the negative prostate effects in men or hair growth in women that is associated with steroidal treatment.

According to Dr. Dobs, Phase III of the trial will assess the effects of a 3mg/day dosage of Enobosarm for the prevention and treatment of muscle wasting in patients with non-small cell lung cancer.

The usage of a drug like Enobosarm could greatly aid in the health of mesothelioma patients when receiving radiation and chemotherapy treatments.

The national mesothelioma law firm of Baron and Budd has been dedicated to the development of mesothelioma research and treatment and is excited to report on the improvement in medications for mesothelioma patients. The firm is proud of its work with organizations like the National Comprehensive Cancer Network and Cure Media Group as well as several others, and it committed to relating any relevant information to the people affected by mesothelioma.

For more information about Enobosarm and the clinical trials at John Hopkins University Medical Center, read the more about the study in "Prevalence and Impact of Hypogonadism in Cancer Patients with Muscle Wasting in a Phase IIb Enobosarm Trial," published June 24, 2012.

Amanda Theaker Baron & Budd 214.991.1051 Email Information

More here:
The National Mesothelioma Law Firm of Baron and Budd Reports on a New Drug that Could Improve the Health of ...

Contact Us Today For A Free Consultation

Name (*):

Email (*):

Phone (*):

Program (*):

State (*):

Age (30+ only):

(*) - Required

hormone replacement specialist therapy.webp
Related Posts

How useful was this post?

Click on a smiley face to rate it!

Average rating / 5. Vote count:

No votes so far! Be the first to rate this post.

Word Count: 378

Comments are closed.

testosterone chart low testerone in men signs.webp
side effects of low testosterone levels.webp
how to increase levels